title: Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide.
abstract: Thalidomide, a sedative agent previously associated with severe fetal malformations, has anti-angiogenic activity. We describe the antitumor effects of thalidomide in a patient with hepatocellular carcinoma that was refractory to systemic and intraarterial therapy.
authors.affiliation: Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, USA.
authors.forename: Y Z
authors.initials: YZ
authors.lastname: Patt
authors.forename: M M
authors.initials: MM
authors.lastname: Hassan
authors.forename: R D
authors.initials: RD
authors.lastname: Lozano
authors.forename: L M
authors.initials: LM
authors.lastname: Ellis
authors.forename: J A
authors.initials: JA
authors.lastname: Peterson
authors.forename: K A
authors.initials: KA
authors.lastname: Waugh
mesh_terms: D000284:Administration, Oral; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D013792:Thalidomide / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000509:alpha-Fetoproteins; D013792:Thalidomide